Recombinase Assisted Cas9-mediated gene Repair (RACeR) is a collection of enzymes that significantly improve the capabilities of existing sequence specific double-stranded DNA nuclease products like CRISPR, TALEN and ZFN. The tool can function as either a supplemental kit or a stand-alone product, and edits and repairs genes with high specificity and with efficiencies up to 3 times better than CRISPR-Cas9 alone.
Inven2 AS seeks a licensee of the technology.
Currently, CRISPR and related tools, favor the error prone non-homologues end-joining pathway (NHEJ) to repair induced DNA breaks; therefore, CRISPR-Cas9 is principally used to create errors causing gene deletions and knockouts. However, by supplying an optimized variant of recombinases (RACeR) with Cas9 (or other double-stranded nucleases) and a homologous recombination substrate, we see increased levels of HDR and an improved efficacy of 60% in targeting repair or sequence insertions, compared to 20% when using Cas9 alone.
The technology is adaptable and should efficiently incorporate any sequence into any genome. There are no direct competing solutions of similar genetic tools on the market today. This technology can be rapidly marketable and has the propensity to procure a similar or perhaps greater market share than the CRISPR-Cas9 technology.
Patent applications are pending in US, EPO, China, Canada and Chile with patent priority data of June 2016.